C4 Therapeutics (CCCC) Investor Presentation - Slideshow

0- -- Patient 1 - Patient 2 -25 - Patient 3 cent Change e -50 -75 -100- 20 0 10 15 Day 15 AUC0-24h (hr*ng/mL) — Simulated IKZF3 Degradation 50 µg © 2023 C4 Therapeutics, Inc. Potential for CFT7455 to replace other IKFZ1/3 degraders and become a backbone therapy CFT7455 © 2023 C4 Therapeutics, Inc. No approved therapies specifically for synovial sarcoma • Potent | --- | --- | --- | --- | |--------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | Protein degraded. | | | | ...